Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

Combination bevacizumab (BV) with radiotherapy and temozolomide (TMZ) is safe and feasible in patients with newly-diagnosed glioblastoma multiforme (GBM), but low response rates do not favor a neoadjuvant approach, according to a recent study published in The Oncologist.

Myra van Linde, MD, and fellow researchers from the VU Medical Center in The Netherlands observed 19 patients, with six after biopsy and 13 after resection.

“We hypothesized that a neoadjuvant treatment strategy for patients with newly-diagnosed GBM using chemoradiotherapy plus BV would improve respectability and thus survival,” the authors noted.

In their phase II trial, patients received radiotherapy with combination BV and TMZ on days 1, 14, and 28, followed by six monthly cycles of TMZ on days 1 to 5.

They found that the overall response rate was 26 percent, with three who had a complete response after resection and two who had complete response after resection followed by chemoradiation with BV. Median overall survival was 16 months which was similar to a matched control group that received standard chemoradiotherapy at the VU Medical Center.

Progesterone Potential Therapy Against Glioblastoma
Combination bevacizumab with radiotherapy and temozolomide is safe in glioblastoma, but low response rates do not favor a neoadjuvant approach.
The authors performed a phase II trial of the treatment strategy of BV plus chemoradiation to determine the safety of this combination in patients who had already undergone primary surgery for their GBM.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs